Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2007 1
2008 1
2010 1
2011 1
2012 2
2013 1
2014 1
2015 4
2016 7
2017 3
2018 1
2019 3
2020 2
2021 3
2022 1
Text availability
Article attribute
Article type
Publication date

Search Results

29 results
Results by year
Filters applied: . Clear all
Page 1
Sunlight exposure exerts immunomodulatory effects to reduce multiple sclerosis severity.
Ostkamp P, Salmen A, Pignolet B, Görlich D, Andlauer TFM, Schulte-Mecklenbeck A, Gonzalez-Escamilla G, Bucciarelli F, Gennero I, Breuer J, Antony G, Schneider-Hohendorf T, Mykicki N, Bayas A, Then Bergh F, Bittner S, Hartung HP, Friese MA, Linker RA, Luessi F, Lehmann-Horn K, Mühlau M, Paul F, Stangel M, Tackenberg B, Tumani H, Warnke C, Weber F, Wildemann B, Zettl UK, Ziemann U, Müller-Myhsok B, Kümpfel T, Klotz L, Meuth SG, Zipp F, Hemmer B, Hohlfeld R, Brassat D, Gold R, Gross CC, Lukas C, Groppa S, Loser K, Wiendl H, Schwab N; German Competence Network Multiple Sclerosis (KKNMS) and the BIONAT Network. Ostkamp P, et al. Among authors: pignolet b. Proc Natl Acad Sci U S A. 2021 Jan 5;118(1):e2018457118. doi: 10.1073/pnas.2018457118. Proc Natl Acad Sci U S A. 2021. PMID: 33376202 Free PMC article.
Reply.
Fissolo N, Pignolet B, Brassat D, Comabella M. Fissolo N, et al. Among authors: pignolet b. Ann Neurol. 2017 Oct;82(4):647-648. doi: 10.1002/ana.25039. Epub 2017 Oct 4. Ann Neurol. 2017. PMID: 28869673 No abstract available.
Transgenic mouse models of multiple sclerosis.
Scheikl T, Pignolet B, Mars LT, Liblau RS. Scheikl T, et al. Among authors: pignolet b. Cell Mol Life Sci. 2010 Dec;67(23):4011-34. doi: 10.1007/s00018-010-0481-9. Epub 2010 Aug 17. Cell Mol Life Sci. 2010. PMID: 20714779 Review.
Teriflunomide treatment for multiple sclerosis modulates T cell mitochondrial respiration with affinity-dependent effects.
Klotz L, Eschborn M, Lindner M, Liebmann M, Herold M, Janoschka C, Torres Garrido B, Schulte-Mecklenbeck A, Gross CC, Breuer J, Hundehege P, Posevitz V, Pignolet B, Nebel G, Glander S, Freise N, Austermann J, Wirth T, Campbell GR, Schneider-Hohendorf T, Eveslage M, Brassat D, Schwab N, Loser K, Roth J, Busch KB, Stoll M, Mahad DJ, Meuth SG, Turner T, Bar-Or A, Wiendl H. Klotz L, et al. Among authors: pignolet b. Sci Transl Med. 2019 May 1;11(490):eaao5563. doi: 10.1126/scitranslmed.aao5563. Sci Transl Med. 2019. PMID: 31043571 Clinical Trial.
IFN-γ is a therapeutic target in paraneoplastic cerebellar degeneration.
Yshii L, Pignolet B, Mauré E, Pierau M, Brunner-Weinzierl M, Hartley O, Bauer J, Liblau R. Yshii L, et al. Among authors: pignolet b. JCI Insight. 2019 Apr 4;4(7):e127001. doi: 10.1172/jci.insight.127001. eCollection 2019 Apr 4. JCI Insight. 2019. PMID: 30944244 Free PMC article.
BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
Cohen M, Mondot L, Bucciarelli F, Pignolet B, Laplaud DA, Wiertlewski S, Brochet B, Ruet A, Defer G, Derache N, Vermersch P, Zephir H, Debouverie M, Mathey G, Berger E, Cappé C, Labauge P, Carra C, De Seze J, Bigaut K, Brassat D, Lebrun-Frenay C. Cohen M, et al. Among authors: pignolet b. Mult Scler. 2021 Sep;27(10):1556-1563. doi: 10.1177/1352458520969145. Epub 2020 Oct 30. Mult Scler. 2021. PMID: 33124504
Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
Fissolo N, Pignolet B, Rio J, Vermersch P, Ruet A, deSèze J, Labauge P, Vukusic S, Papeix C, Martinez-Almoyna L, Tourbah A, Clavelou P, Moreau T, Pelletier J, Lebrun-Frenay C, Bourre B, Defer G, Montalban X, Brassat D, Comabella M. Fissolo N, et al. Among authors: pignolet b. Neurol Neuroimmunol Neuroinflamm. 2021 Apr 26;8(4):e1003. doi: 10.1212/NXI.0000000000001003. Print 2021 Jul. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33903203 Free PMC article. Clinical Trial.
Prospective validation of the PML risk biomarker l-selectin and influence of natalizumab extended intervals.
Schwab N, Schneider-Hohendorf T, Pignolet B, Bucciarelli F, Scandella L, Ciron J, Biotti D, Lebrun-Frenay C, Mathey G, Clavelou P, Pelletier J, Ostkamp P, Meinl I, Windhagen S, Klotz L, Gross CC, Meuth SG, Deisenhammer F, Brassat D, Wiendl H; Best-MS Study Group. Schwab N, et al. Among authors: pignolet b. Neurology. 2019 Sep 17;93(12):550-554. doi: 10.1212/WNL.0000000000008135. Epub 2019 Aug 22. Neurology. 2019. PMID: 31439633 No abstract available.
29 results